Insulet Co. (NASDAQ:PODD) Stock Holdings Lifted by Cerity Partners LLC

Cerity Partners LLC lifted its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 78.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,193 shares of the medical instruments supplier's stock after purchasing an additional 4,484 shares during the quarter. Cerity Partners LLC's holdings in Insulet were worth $2,372,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Wedmont Private Capital boosted its position in shares of Insulet by 3.5% during the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier's stock worth $326,000 after purchasing an additional 48 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd lifted its position in shares of Insulet by 4.7% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier's stock valued at $250,000 after acquiring an additional 48 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Insulet by 1.1% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier's stock worth $1,264,000 after acquiring an additional 66 shares during the period. Finally, Greenleaf Trust boosted its holdings in shares of Insulet by 4.2% during the third quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier's stock worth $415,000 after purchasing an additional 72 shares during the last quarter.

Insulet Price Performance

Shares of PODD traded down $0.29 during midday trading on Monday, reaching $266.49. The stock had a trading volume of 609,741 shares, compared to its average volume of 769,367. The firm's 50 day moving average price is $244.40 and its 200-day moving average price is $214.37. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The company has a market capitalization of $18.69 billion, a P/E ratio of 45.68, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Analyst Ratings Changes

A number of equities analysts have weighed in on PODD shares. Barclays lifted their price target on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a report on Monday, November 11th. Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research report on Tuesday, October 1st. Raymond James increased their target price on Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research note on Monday, October 14th. Sanford C. Bernstein assumed coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price objective for the company. Finally, Piper Sandler lifted their target price on Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average target price of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.